Adaptimmune Reports First Quarter Financial Results and Business Update
06 mai 2021 07h30 HE
|
Adaptimmune Therapeutics plc
- Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO - - First preclinical update from HLA-independent TCR (HiT) targeting mesothelin at ASGCT - - Enrollment momentum in...
Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT
27 avr. 2021 16h30 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical...
Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021
22 avr. 2021 08h00 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 22, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results...
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
25 févr. 2021 07h30 HE
|
Adaptimmune Therapeutics plc
- Outlined strategy to build integrated cell therapy company and the Company’s “2-2-5-2” five-year core value drivers - - Reported compelling durable responses in patients with synovial sarcoma,...
Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021
11 févr. 2021 08h00 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results...
Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day
20 nov. 2020 07h30 HE
|
Adaptimmune Therapeutics plc
- SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma - - Next registration directed trial initiating with ADP-A2M4CD8 in 1H 2021 for...
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
19 nov. 2020 09h00 HE
|
Adaptimmune Therapeutics plc
- Data support confidence in SPEARHEAD-1 as a registrational trial - - Projected to complete recruitment of all patients in Q1 2021 - - Median duration of response was 28 weeks with ongoing...
Adaptimmune to Host Virtual Investor Day on Friday, November 20th
12 nov. 2020 08h00 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor...
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
09 nov. 2020 15h18 HE
|
Adaptimmune Therapeutics plc
- Data support continued development of ADP-A2M4CD8 - - On track to start Phase 2 trial in gastroesophageal cancers in the first half of 2021 - PHILADELPHIA, Pa. and OXFORDSHIRE, UK., Nov. 09, 2020...
Adaptimmune Reports Q3 Financial Results and Business Update
05 nov. 2020 07h30 HE
|
Adaptimmune Therapeutics plc
- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients - - Safety and response data from dose escalation...